Showing posts with label ChronicIllness. Show all posts
Showing posts with label ChronicIllness. Show all posts

Wednesday, October 21, 2026

The Extraordinary Influence of The Lymphatic System On Our Health

Eiko Ojala

I placed the cold, jade rolling pin under my cheekbone and gently glided it to the edge of my face. To be honest, I felt a bit like a piece of pastry. But my grandma assured me that I was engaging in a serious traditional Chinese practice that would make my skin glow and my face less puffy. It would be more than a decade before face rolling became the next big beauty fad on social media – and several years more before I realised its supposed benefits may hinge on the lymphatic system, a network spanning the entire body, consisting largely of thread-like vessels and bean-shaped nodes……..Continue reading…..

By Carissa Wong

Source: New Scientist

.

Critics:

Unlike the circulatory system, which is a closed system, the lymphatic system is open. Lymph originates in the interstitial fluid that leaks from blood in the circulatory system into the tissues of the body. This fluid carries nutrients to the cells and collects waste products, bacteria, and damaged cells, before draining into the lymphatic vessels as lymph.

The circulatory system processes an average of 20 litres (5.3 US gal) of blood per day through capillary filtration, which removes plasma from the blood. Roughly 17 litres (4.5 US gal) of the filtered blood is reabsorbed directly into the blood vessels, while the remaining 3 litres (0.79 US gal) are left in the interstitial fluid. The lymphatic system provides an accessory return route to the blood for this remainder.

 

The other main function is that of immune defense. Lymph is very similar to blood plasma, in that it contains waste products and cellular debris, together with bacteria and proteins. The cells of the lymph are mostly lymphocytes. Associated lymphoid organs are composed of lymphoid tissue, and are the sites either of lymphocyte production or of lymphocyte activation. These include the lymph nodes (where the highest lymphocyte concentration is found), the spleen, the thymus, and the tonsils. Lymphocytes are initially generated in the bone marrow.

The lymphoid organs also contain other types of cells such as stromal cells for support. Lymphoid tissue is also associated with mucosas such as mucosa-associated lymphoid tissue (MALT). These vessels carry the lymph throughout the body, passing through numerous lymph nodes which filter out unwanted materials such as bacteria and damaged cells. Lymph then passes into much larger lymph vessels known as lymph ducts.

The right lymphatic duct drains the right side of the region and the much larger left lymphatic duct, known as the thoracic duct, drains the left side of the body. The ducts empty into the subclavian veins to return to the blood circulation. Lymph is moved through the system by muscle contractions. In some vertebrates, a lymph heart is present that pumps the lymph to the veins.

The lymphatic system was first described in the 17th century independently by Olaus Rudbeck and Thomas Bartholin. The lymphatic system consists of a conducting network of lymphatic vessels, lymphoid organs, lymphoid tissues, and the circulating lymph. The primary (or central) lymphoid organs, including the thymus, bone marrow, fetal liver and yolk sac, are responsible for generating lymphocytes from immature progenitor cells in the absence of antigens.

The thymus and the bone marrow constitute the primary lymphoid organs involved in the production and early clonal selection of lymphocyte tissues.Bird species’ primary lymphoid organs include the bone marrow, thymus, bursa of Fabricius, and yolk sac. Bone marrow is responsible for both the creation of T cell precursors and the production and maturation of B cells, which are important cell types of the immune system. From the bone marrow, B cells immediately join the circulatory system and travel to secondary lymphoid organs in search of pathogens.

T cells, on the other hand, travel from the bone marrow to the thymus, where they develop further and mature. Mature T cells then join B cells in search of pathogens. The other 95% of T cells begin a process of apoptosis, a form of programmed cell death: T cells that cannot interact strongly enough with self-antigens are eliminated during T cell § Positive selection, and T cells that attack the body’s own proteins are eliminated during § Negative selection.

The thymus increases in size from birth in response to postnatal antigen stimulation. It is most active during the neonatal and pre-adolescent periods. The thymus is located between the inferior neck and the superior thorax. At puberty, by the early teens, the thymus begins to atrophy and regress, with adipose tissue mostly replacing the thymic stroma. However, residual T cell lymphopoiesis continues throughout adulthood, providing some immune response.

The thymus is where the T lymphocytes mature and become immunocompetent. The loss or lack of the thymus results in severe immunodeficiency and subsequent high susceptibility to infection. In most species, the thymus consists of lobules divided by septa, which are made up of epithelium, which is often considered an epithelial organ. T cells mature from thymocytes, proliferate, and undergo a selection process in the thymic cortex before entering the medulla to interact with epithelial cells.

Research on bony fish showed a buildup of T cells in the thymus and spleen of lymphoid tissues in salmon and showed that there are not many T cells in non-lymphoid tissues. The thymus provides an inductive environment for developing T cells from hematopoietic progenitor cells. In addition, thymic stromal cells allow for the selection of a functional and self-tolerant T cell repertoire. Therefore, one of the most important roles of the thymus is the induction of central tolerance.

However, the thymus is not where the infection is fought, as the T cells have yet to become immunocompetent. The secondary (or peripheral) lymphoid organs, which include lymph nodes and the spleen, maintain mature naive lymphocytes and initiate an adaptive immune response. The secondary lymphoid organs are the sites of lymphocyte activation by antigens. Activation leads to clonal selection and affinity maturation. Mature lymphocytes recirculate between the blood and the secondary lymphoid organs until they encounter their specific antigen.

The lymphatic vessels, also called lymph vessels, are thin-walled vessels that conduct lymph between different parts of the body. They include the tubular vessels of the lymph capillaries, and the larger collecting vessels – the right lymphatic duct and the thoracic duct (the left lymphatic duct). The lymph capillaries are mainly responsible for the absorption of interstitial fluid from the tissues, while lymph vessels propel the absorbed fluid forward into the larger collecting ducts, where it ultimately returns to the bloodstream via one of the subclavian veins.

The tissues of the lymphatic system are responsible for maintaining the balance of the body fluids. Its network of capillaries and collecting lymphatic vessels efficiently drain and transport extravasated fluid, along with proteins and antigens, back to the circulatory system. Numerous intraluminal valves in the vessels ensure a unidirectional flow of lymph without reflux. Two valve systems, a primary and a secondary valve system, are used to achieve this unidirectional flow.

The capillaries are blind-ended, and the valves at the ends of capillaries use specialised junctions together with anchoring filaments to allow a unidirectional flow to the primary vessels. When interstitial fluid increases, it causes swelling that stretches collagen fibers anchored to adjacent connective tissue, opening the unidirectional valves at the ends of these capillaries and facilitating the entry and subsequent drainage of excess lymph fluid.

The collecting lymphatics, however, propel the lymph by the combined actions of the intraluminal valves and lymphatic muscle cells. The development of the lymphatic vascular system is a highly coordinated process essential for maintaining fluid homeostasis, immune surveillance, and lipid absorption. Lymphangiogenesis, the formation of lymphatic vessels from pre-existing ones, is primarily driven by the migration and differentiation of lymphatic endothelial cells (LECs) under the influence of molecular signals such as vascular endothelial growth factor C (VEGF-C).

The maturation and specialization of lymphatic vessels involve complex interactions with surrounding tissues, ensuring the proper function of lymphatic drainage and Immune cell trafficking. Recent advances in vitro and in vivo studies have provided deeper insights into the mechanisms regulating lymphatic vascular development, as well as the processes governing its maintenance and aging. Understanding these pathways is critical, as disruptions in lymphatic development are implicated in congenital disorders, inflammatory diseases, and cancer metastasis.

Lymphatic tissues begin to develop by the end of the fifth week of embryonic development. Lymphatic vessels develop from lymph sacs that arise from developing veins, which are derived from mesoderm. The first lymph sacs to appear are the paired jugular lymph sacs at the junction of the internal jugular and subclavian veins. From the jugular lymph sacs, lymphatic capillary plexuses spread to the thorax, upper limbs, neck, and head.

Some of the plexuses enlarge and form lymphatic vessels in their respective regions. Each jugular lymph sac retains at least one connection with its jugular vein, the left one developing into the superior portion of the thoracic duct. The spleen develops from mesenchymal cells between layers of the dorsal mesentery of the stomach. The thymus arises as an outgrowth of the third pharyngeal pouch.

Patrick Helfer: lymphatic drainage as an inner journey

.

LymphaticSystem ,WellnessJourney ,HealthAwareness ,BodyDetox ,ImmunityBoost ,NaturalHealing ,HealthyLiving ,LymphaticHealth ,ChronicIllness ,StayActive ,HolisticHealth ,Detoxification ,NutritionMatters ,SelfCare ,HealthEducation ,BodyBalance ,FitnessGoals ,WellnessTips ,HealthyLifestyle

Saturday, October 17, 2026

Ancient DNA Helps Solve Multiple Sclerosis Mystery in Europe

(MICROGEN IMAGES/SCIENCE PHOTO LIBRARY/Getty Images)

The secrets of our ancestors might hold the key to why multiple sclerosis (MS) is more common among white, northern Europeans than among Europe’s more southern populations. While scientists have found hundreds of genes to date that are associated with MS, up to a fifth of northern Europeans have a genetic variant, called HLA-DRB1*15:01, that conveys a threefold higher risk of developing the autoimmune disease. Where this variant came from and why it persisted and spread is a mystery. An international team of researchers, led by William Barrie from the University of Cambridge, now thinks they are on to a new lead…..…Story continues…

By: Carly Cassella

Source: ScienceAlert

.

Critics:

Multiple sclerosis (MS) is an autoimmune disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. Being a demyelinating disease, MS disrupts the ability of parts of the nervous system to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.

Symptoms include double vision, vision loss, eye pain, muscle weakness, and loss of sensation or coordination. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). In relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances.

In progressive forms of MS, bodily function slowly deteriorates once symptoms manifest and will steadily worsen if left untreated. While its cause is unclear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include immune dysregulation, genetics, and environmental factors, such as viral infections. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.

No cure for multiple sclerosis is known. Current treatments are aimed at mitigating inflammation and resulting symptoms from acute flares and prevention of further attacks with disease-modifying medications. Physical therapy and occupational therapy, along with patient-centered symptom management, can help with people’s ability to function.

The long-term outcome is difficult to predict; better outcomes are more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks. Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. Nearly one million people in the United States had MS in 2022, and in 2020, about 2.8 million people were affected globally, with rates varying widely in different regions and among different populations.

The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men. MS was first described in 1868 by French neurologist Jean-Martin Charcot. The name “multiple sclerosis” is short for multiple cerebro-spinal sclerosis, which refers to the numerous glial scars (or sclerae – essentially plaques or lesions) that develop on the white matter of the brain and spinal cord.

As multiple sclerosis (MS) lesions can affect any part of the central nervous system, a person with MS can have almost any neurological symptom or sign referable to the central nervous system. Fatigue is one of the most common symptoms of MS. Some 65% of people with MS experience fatigue symptomatology, and of these, some 15–40% report fatigue as their most disabling MS symptom. Autonomic, visual, motor, and sensory problems are also among the most common symptoms.

The specific symptoms are determined by the locations of the lesions within the nervous system, and may include focal loss of sensitivity or changes in sensation in the limbs, such as feeling tingling, pins and needles, or numbness; limb motor weakness/pain, blurred vision, pronounced reflexes, muscle spasms, difficulty with ambulation (walking), difficulties with coordination and balance (ataxia).

Problems with speech or swallowing, visual problems (optic neuritis manifesting as eye pain & vision loss, or nystagmus manifesting as double vision), fatigue, and bladder and bowel difficulties (such as urinary or fecal incontinence or retention), among others. When multiple sclerosis is more advanced, walking difficulties can occur and the risk of falling increases. Difficulties thinking and emotional problems such as depression or unstable mood are also common.

The primary deficit in cognitive function that people with MS experience is slowed information-processing speed, with memory also commonly affected, and executive function less commonly. Intelligence, language, and semantic memory are usually preserved, and the level of cognitive impairment varies considerably between people with MS.

Uhthoff’s phenomenon, a worsening of symptoms due to exposure to higher-than-usual temperatures, and Lhermitte’s sign, an electrical sensation that runs down the back when bending the neck, are particularly characteristic of MS, although may not always be present.

Another presenting manifestation that is rare but highly suggestive of a demyelinating process such as MS is bilateral internuclear ophthalmoplegia, where the patient experiences double vision when attempting to move their gaze to the right & left. Some 60% or more of MS patients find their symptoms, particularly including fatigue, are affected by changes in body temperature.

The main measure of disability and severity is the expanded disability status scale (EDSS), with other measures such as the multiple sclerosis functional composite being increasingly used in research. EDSS is also correlated with falls in people with MS. While it is a popular measure, EDSS has been criticized for some of its limitations, such as relying too much on walking.

The condition begins in 85% of cases as a clinically isolated syndrome (CIS) over a number of days with 45% having motor or sensory problems, 20% having optic neuritis, and 10% having symptoms related to brainstem dysfunction, while the remaining 25% have more than one of the previous difficulties.

Regarding optic neuritis as the most common presenting symptom, people with MS notice sub-acute loss of vision, often associated with pain worsening on eye movement, and reduced colour vision. Early diagnosis of MS-associated optic neuritis helps timely initiation of targeted treatments.

However, it is crucial to adhere to established diagnostic criteria when treating optic neuritis due to the broad range of alternative causes, such as neuromyelitis optica spectrum disorder (NMOSD), and other autoimmune or infectious conditions. The course of symptoms occurs in two main patterns initially:

Either as episodes of sudden worsening that last a few days to months (called relapses, exacerbations, bouts, attacks, or flare-ups) followed by improvement (85% of cases) or as a gradual worsening over time without periods of recovery (10–15% of cases).A combination of these two patterns may also occur or people may start in a relapsing and remitting course that then becomes progressive later on.

Relapses are usually unpredictable, occurring without warning. Exacerbations rarely occur more frequently than twice per year. Some relapses, however, are preceded by common triggers and they occur more frequently during spring and summer. Similarly, viral infections such as the common cold, influenza, or gastroenteritis increase their risk. Stress may also trigger an attack.

Many events have been found not to affect rates of relapse requiring hospitalization including vaccination, breast feeding, physical trauma, and Uhthoff’s phenomenon.

Wednesday, October 7, 2026

Should Your Benefits Plan Cover Weight Loss Drugs Like Ozempic

Getty

While many employer plans cover the weight-loss drug Ozempic as a diabetes treatment, only 22 percent of U.S. employers cover any kind of prescription drugs for weight loss, according to a survey from the International Foundation of Employee Benefit Plans, a nonprofit membership organization that provides information for those working in the employee benefits industry. That could change soon. On August 9, 2023, Wegovy drugmaker Novo Nordisk reported the results of a new study that showed once-weekly Wegovy injections cut the likelihood of serious cardiac events such as heart attacks, strokes, and cardiovascular deaths…..….Story continues…

Source: Inc

.

Critics:

Ozempic, the semaglutide injection used for T2D treatment, has a list price of $936 in the United States and $169 in Japan. Prices were $147 in Canada, $144 in Switzerland, $103 in Germany and Netherlands, $96 in Sweden, $93 in the United Kingdom, and $87 in Australia. France had the lowest price at $83.” (21 August 2023; figures refer to a one-month supply).

In the US, Wegovy has a list price of $1,349.02 per month as of 2022 suggesting that because of the high costs many people “who could most benefit from weight loss may be unable to afford such expensive drugs”. High costs of Ozempic prompted some insurance companies to investigate and refuse to cover patients with what the companies considered was insufficient evidence to support a diabetes diagnosis, alleging off-label prescribing for weight loss.

In the UK, semaglutide is available on NHS prescription for diabetes at nominal or no cost to patients. It is also available for obesity, limited to treatment for two years. High demand caused worldwide supply shortages of semaglutide in 2023; new UK prescriptions were not issued during the shortage. By 2023, Novo Nordisk had become the most valuable corporation in the European Union, worth more than US$500 billion, and accounted for almost all recent economic growth in Denmark.

Profits from Novo Nordisk generate returns for the Novo Nordisk Foundation, which holds the controlling stake in Novo Nordisk. The profits results in increased Danish tax revenues and employment. Novo Nordisk added 3,500 jobs in Denmark in 2022, bringing the total in the country to 21,000 employees, out of 59,000 worldwide.

In October 2023, there were reports of counterfeit Ozempic pens being sold in Europe. The pens possibly contained insulin, and led to several people being hospitalised with hypoglycemia and seizures. In December 2023, the FDA issued a warning about counterfeit Ozempic in the United States.

Some compounded versions have been found to contain salts of semaglutide including the sodium and the acetate in an attempt to avoid the patent of the base semaglutide product. These are not evaluated for safety and effectiveness by and thus are considered not shown to be safe or effective by the US Food and Drug Administration (FDA).

A 2014 meta-analysis found that semaglutide may be effective in lowering liver enzymes (transaminitis) and improving certain radiologically observed features of metabolic dysfunction–associated steatotic liver disease. French national health care insurance system database had previously suggested 1–3 years use of glucagon like peptide-1 receptor agonists like exenatide, liraglutide and dulaglutide may be linked with increased occurrence of thyroid cancer. Semaglutide belongs to the same family of medicine.

A meta-analysis involving data from 37 randomized controlled trials and 19 real world studies (46,719 patients) showed that semaglutide use over 18 months was not associated with increased risks of any cancer, supported by a high grade of evidence. In July 2023, the Icelandic Medicines Agency reported two cases of suicidal thoughts and one case of self-injury of users of the injection, prompting a safety assessment of Ozempic, Wegovy, Saxenda, and similar drugs.

In January 2024, a preliminary review conducted by the FDA confirmed no evidence had been found to suggest that the medicine causes suicidal thoughts or actions. Semaglutide has shown potential to reduce interest in alcohol consumption among users. Scientists speculate that semaglutide may influence brain regions involved in addiction and appetite regulation, although the exact mechanisms remain under study.

Animal research has indicated that drugs similar to semaglutide can reduce alcohol intake. Semaglutide and similar drugs, such as dulaglutide and liraglutide, have been used to treat binge eating disorder (BED), as they can successfully minimize obsessive thoughts about food and binging urges.

Some users of these drugs have reported significant reduction in what is colloquially known as “food noise” (constant, unstoppable thoughts about eating despite not being physically hungry), which can be a factor of BED.

Leave a Reply

The Turkish Hiking Trail Named Most Beautiful In The World By Time Out

Shutterstock Looking for a digital detox? We all need to get into nature every so often, and sometimes touching grass isn’t enough. Sometime...